Astria Therapeutics Dirección
Dirección controles de criterios 3/4
El CEO de Astria Therapeutics' es Jill Milne , nombrado en Jun 2008, tiene una permanencia de 16.17 años. compensación anual total es $2.96M, compuesta por 20.4% salario y 79.6% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.008% de las acciones de la empresa, por valor de $48.95K. La antigüedad media del equipo directivo y de la junta directiva es de 4.4 años y 8.8 años, respectivamente.
Información clave
Jill Milne
Chief Executive Officer (CEO)
US$3.0m
Compensación total
| Porcentaje del salario del CEO | 20.4% |
| Permanencia del CEO | 16.3yrs |
| Participación del CEO | 0.008% |
| Permanencia media de la dirección | 4.5yrs |
| Promedio de permanencia en la Junta Directiva | 8.9yrs |
Actualizaciones recientes de la dirección
Recent updates
We're Hopeful That Astria Therapeutics (NASDAQ:ATXS) Will Use Its Cash Wisely
Jul 11
Astria Therapeutics: A Cash-Rich Entrant In An Increasingly Crowded Field
Jun 24Astria Therapeutics: Too Much Risk, Too Little Reward Despite Near-Term Data Readout
Feb 04We Think Astria Therapeutics (NASDAQ:ATXS) Can Afford To Drive Business Growth
Dec 10We Think Astria Therapeutics (NASDAQ:ATXS) Can Afford To Drive Business Growth
Jul 27We're Not Very Worried About Astria Therapeutics' (NASDAQ:ATXS) Cash Burn Rate
Apr 03Here's Why We're Not Too Worried About Astria Therapeutics' (NASDAQ:ATXS) Cash Burn Situation
Nov 30We're Hopeful That Astria Therapeutics (NASDAQ:ATXS) Will Use Its Cash Wisely
Aug 01Dr. Chris Morabito is the new medical chief of Astria Therapeutics
Jul 15Catabasis Pharmaceuticals: Transformation Through Quellis Biosciences Acquisition
Jun 30Catabasis Pharmaceuticals skyrockets 44% on 7.5% ownership disclosure by RA Capital
Jun 15Catabasis Pharma shares surge after Quellis Biosciences deal
Jan 29Will Catabasis Pharmaceuticals (NASDAQ:CATB) Spend Its Cash Wisely?
Dec 10
Catabasis' Catastrophic Failure, And Other News: The Good, Bad And Ugly Of Biopharma
Oct 29Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$93m |
| Mar 31 2024 | n/a | n/a | -US$82m |
| Dec 31 2023 | US$3m | US$602k | -US$73m |
| Sep 30 2023 | n/a | n/a | -US$55m |
| Jun 30 2023 | n/a | n/a | -US$49m |
| Mar 31 2023 | n/a | n/a | -US$48m |
| Dec 31 2022 | US$2m | US$568k | -US$52m |
| Sep 30 2022 | n/a | n/a | -US$48m |
| Jun 30 2022 | n/a | n/a | -US$44m |
| Mar 31 2022 | n/a | n/a | -US$65m |
| Dec 31 2021 | US$3m | US$536k | -US$219m |
| Sep 30 2021 | n/a | n/a | -US$219m |
| Jun 30 2021 | n/a | n/a | -US$222m |
| Mar 31 2021 | n/a | n/a | -US$199m |
| Dec 31 2020 | US$1m | US$520k | -US$37m |
| Sep 30 2020 | n/a | n/a | -US$35m |
| Jun 30 2020 | n/a | n/a | -US$31m |
| Mar 31 2020 | n/a | n/a | -US$28m |
| Dec 31 2019 | US$1m | US$501k | -US$26m |
| Sep 30 2019 | n/a | n/a | -US$26m |
| Jun 30 2019 | n/a | n/a | -US$25m |
| Mar 31 2019 | n/a | n/a | -US$24m |
| Dec 31 2018 | US$1m | US$476k | -US$26m |
| Sep 30 2018 | n/a | n/a | -US$25m |
| Jun 30 2018 | n/a | n/a | -US$27m |
| Mar 31 2018 | n/a | n/a | -US$27m |
| Dec 31 2017 | US$633k | US$462k | -US$27m |
Compensación vs. Mercado: La compensación total ($USD2.96M) de Jill está en línea con el promedio de empresas de tamaño similar en el mercado US ($USD3.30M).
Compensación vs. Ingresos: La compensación de Jill ha aumentado mientras la empresa no es rentable.
CEO
Jill Milne (56 yo)
16.3yrs
Permanencia
US$2,955,504
Compensación
Ms. Jill C. Milne, PhD is a Co-founder of Astria Therapeutics, Inc. (formerly known as Catabasis Pharmaceuticals, Inc.), has been its Director, President and Chief Executive Officer since June 2008. She se...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Co-Founder | 16.3yrs | US$2.96m | 0.0078% $ 53.6k | |
| CFO & Treasurer | 4.8yrs | US$1.35m | 0% $ 0 | |
| Chief Medical Officer | 2.2yrs | US$1.32m | 0% $ 0 | |
| Chief Legal Officer | 4.3yrs | US$845.83k | 0% $ 0 | |
| Senior Vice President of Human Resources | 3.4yrs | sin datos | sin datos | |
| Chief Business Officer | 7yrs | sin datos | sin datos | |
| Chief Commercial Officer | 5yrs | sin datos | sin datos | |
| Senior Vice President of Pharmaceutical Sciences & Technical Operations | 1.2yrs | sin datos | sin datos |
4.5yrs
Permanencia media
54.5yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de ATXS se considera experimentado (4.4 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Co-Founder | 16.3yrs | US$2.96m | 0.0078% $ 53.6k | |
| Independent Director | 8.4yrs | US$157.67k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Independent Chairman of the Board | 10.7yrs | US$194.17k | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Independent Director | 5.7yrs | US$163.67k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | 8.9yrs | US$589.63k | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos |
8.9yrs
Permanencia media
70yo
Promedio de edad
Junta con experiencia: La junta directiva de ATXS se considera experimentada (8.8 años de antigüedad promedio).